This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): LDP-02; MLN0002, MLN-0002, MLN02
Description: MLN02 is a humanized monoclonal antibody that binds the T cell integrin known as a4b7. In preclinical experiments, binding to a4b7 prevents the migration of immune response-mediating T cells to the gastrointestinal tract. It is hoped that this biological effect will diminish various T cell-mediated processes underlying Crohn disease and ulcerative colitis.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Genentech and LeukoSite (since acquired by Millennium) partnered in December 1997 to develop MLN02.
In April 2008, Takeda Pharmaceutical and Millennium Pharmaceuticals announced that they entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The acquisition closed in May 2008.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Roche Holding AG
Additional information available to subscribers only: